Foghorn Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Depreciation & Amortization Growth & History (FHTX)
Foghorn Therapeutics's depreciation and amortization was $3.3M for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.3M | $212,000 | +6.79% |
| 2024 | 2024-12-31 | $3.1M | −$331,000 | −9.59% |
| 2023 | 2023-12-31 | $3.5M | $130,000 | +3.91% |
| 2022 | 2022-12-31 | $3.3M | $94,000 | +2.91% |
| 2021 | 2021-12-31 | $3.2M | $1.9M | +143.18% |
| 2020 | 2020-12-31 | $1.3M | $634,000 | +91.49% |
| 2019 | 2019-12-31 | $693,000 | — | — |
Foghorn Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $200,000 | −$700,000 | −77.78% |
| Q1 2026 | 2026-03-31 | $238,000 | −$589,000 | −71.22% |
| Q4 2025 | 2025-12-31 | $802,000 | — | — |
| Q3 2025 | 2025-09-30 | $900,000 | $200,000 | +28.57% |
| Q2 2025 | 2025-06-30 | $900,000 | $100,000 | +12.50% |
| Q1 2025 | 2025-03-31 | $827,000 | −$8,000 | −0.96% |
| Q3 2024 | 2024-09-30 | $700,000 | −$200,000 | −22.22% |
| Q2 2024 | 2024-06-30 | $800,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $835,000 | −$24,000 | −2.79% |
| Q3 2023 | 2023-09-30 | $900,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $800,000 | $0 | 0.00% |
| Q1 2023 | 2023-03-31 | $859,000 | $48,000 | +5.92% |
| Q3 2022 | 2022-09-30 | $900,000 | $100,000 | +12.50% |
| Q2 2022 | 2022-06-30 | $800,000 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $811,000 | $39,000 | +5.05% |
| Q3 2021 | 2021-09-30 | $800,000 | $500,000 | +166.67% |
| Q2 2021 | 2021-06-30 | $800,000 | $600,000 | +300.00% |
| Q1 2021 | 2021-03-31 | $772,000 | $517,000 | +202.75% |
| Q3 2020 | 2020-09-30 | $300,000 | — | — |
| Q2 2020 | 2020-06-30 | $200,000 | — | — |
| Q1 2020 | 2020-03-31 | $255,000 | — | — |
Foghorn Therapeutics depreciation and amortization trends
Over the last five fiscal years, Foghorn Therapeutics's depreciation and amortization increased from $1.3M to $3.3M, a change of $2.0M. The latest reported quarter, Q2 2026, shows $200,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗